Aurobindo Pharma Ltd.

Company Overview

Founded in 1986, Aurobindo Pharma is based in Hyderabad, India. The firm manufactures generic pharmaceuticals and APIs, and its 24 manufacturing and packaging facilities have been inspected and approved by several regulatory agencies, including the U.S. FDA, the U.K. MHRA, WHO, Health Canada, South Africa’s MCC, and Brazil’s ANVISA. It became a public company in 1992 and listed its shares on the Indian stock exchange in 1995. It offers products in therapeutic areas, including neurosciences (CNS), anti-retroviral, cardiovascular (CVS), anti-diabetics, gastroenterology, and anti-biotics.

After ensuring a foundation of cost-effective production capabilities, the company entered the high-margin specialty generic formulations segment with a global marketing network. The company exports its products to over 150 countries. CuraTeQ Biologics Pvt. Ltd., a wholly owned subsidiary of Aurobindo Pharma, develops biosimilars in immunology and oncology. The company offers many products, of which a few are mentioned in the product portfolio table.

Financial Highlights (FY 2024)

Company's Business Segments

• Sale of Products : This segment Manufacture, Market a wide range of Generic Pharmaceuticals, Active Pharmaceutical Ingredients (APIs) across various therapeutic areas, including Cardiovascular, Central Nervous System, Anti-retroviral, Anti-diabetics, Gastroenterology, Anti-infective. Their product portfolio includes Tablets, Capsules, Injectables, and more.
• Sale of Services : This segment provide Contract Manufacturing services to other pharmaceutical companies. This involves utilizing their manufacturing facilities and expertise to produce pharmaceutical products on behalf of other companies under contract.
• Other Operating Revenue : This segment includes revenue from Scrap Sales, Government Incentive Schemes.